|
|
|
27 Nov 2007 |
Urigen Signs Licensing Agreement with Mattern for Phase II Treatment of Hypogonadism
|
|
27 Nov 2007 |
Isis and Excaliard Collaborate to Develop Antisense Drugs for Local Treatment of Fibrotic Diseases
|
|
21 Nov 2007 |
GNI Announces IND Approval in China for Novel Liver Disease Drug
|
|
20 Nov 2007 |
Anika Therapeutics and Galderma Agree to Terminate License, Development and Supply Agreements
|
|
20 Nov 2007 |
Cytochroma initiates Phase I/II clinical trial of CTAP101 capsules for vitamin D insufficiency in chronic kidney disease
|
|
19 Nov 2007 |
BioXell Announces Start of Phase IIa trial of Elocalcitol in Male Infertility
|
|
19 Nov 2007 |
Quark Announces First Systemic siRNA Dosing
|
|
15 Nov 2007 |
Wyeth Receives FDA Approval of Protonix for Delayed-Release Oral Suspension
|
|
15 Nov 2007 |
FDA approves Mircera: first renal anemia treatment in the US with monthly maintenance dosing
|
|
12 Nov 2007 |
ISTA Pharmaceuticals Presents Results from Two Phase III Clinical Trials of Xibrom(TM) QD (Once-daily) Formulation at the American Academy of Ophthalmology Annual Meeting
|
|
08 Nov 2007 |
Dynogen’s prokinetic drug, DDP733, enters Phase 2b for irritable bowel syndrome with constipation
|
|
06 Nov 2007 |
MacroChem Announces Positive Interim Phase 2 Data for EcoNail(R) in the Treatment of Onychomycosis
|
|
06 Nov 2007 |
Shire announces results of Fosrenol(R) study in pre-dialysis CKD stage 3 & 4 patients
|
|
06 Nov 2007 |
Neurotech Announces Completion of Enrollment of its Phase II/III Retinitis Pigmentosa and Phase II Dry Age Related Macular Degeneration Clinical Studies
|
|
05 Nov 2007 |
SPP100 (Tekturna/Rasilez) Decreases Proteinuria in Diabetic Patients
|
|
05 Nov 2007 |
Curalogic updates from its Phase III clinical study with the ragweed product
|
|
05 Nov 2007 |
Affymax(R) Announces Hematide(TM) Successfully Restores Hemoglobin in Patients with Pure Red Cell Aplasia (PRCA)
|
|
05 Nov 2007 |
Lantibio and TRB Chemedica Announce Licensing Agreement with Alcon for US Development and Marketing of Dry Eye Drug
|
|
02 Nov 2007 |
FlutiformTM - Results of Safety Study
|
|
02 Nov 2007 |
Phase 2 Trial Results for Exelixis' XL784 Presented at the 2007 American Society of Nephrology Conference
|
|
02 Nov 2007 |
Prometic Reports Positive Pre-Clinical Data for PBI-1402 in Anemia Related to Renal Failure
|
|
02 Nov 2007 |
Discovery Labs Submits Response to FDA Approvable Letter for Surfaxin(R) for RDS in Premature Infants
|
|
01 Nov 2007 |
Theravance Announces Initiation of Phase 2 Clinical Program with its MABA Compound in COPD
|
|
31 Oct 2007 |
Sciele Pharma and Plethora Solutions Holdings PLC Announce Initiation of Pivotal Phase III Trials for PSD502 for Premature Ejaculation
|
|
31 Oct 2007 |
Tranzyme Pharma Initiates Dosing of Patients in a Multi-National Phase IIb Clinical Trial for the Treatment of Severe Gastroparesis
|
|
30 Oct 2007 |
Oglemilast, Glenmark's lead molecule for Asthma / COPD receives US FDA nod to initiate further Phase II trials
|
|
26 Oct 2007 |
Sirion Therapeutics Announces Positive Phase III Results For Difluprednate
|
|
23 Oct 2007 |
Speedel Focuses Pipeline on SPP301 and Next Generation Renin Inhibitors
|
|
22 Oct 2007 |
FDA Approves Genzyme's Renvela(TM) for Dialysis Patients
|
|
20 Oct 2007 |
Pivotal Mircera study first to convert dialysis patients from frequent dosing directly to once every four weeks
|
|
19 Oct 2007 |
FDA Announces Revisions to Labels for Cialis, Levitra and Viagra
|
|
18 Oct 2007 |
Theravance Reports Additional Data on Investigational Compound TD-5108 at 2007 American College of Gastroenterology Annual Scientific Meeting
|
|
18 Oct 2007 |
Pro-Pharmaceuticals Novel Carbohydrate Compounds Reverse Liver
|
|
17 Oct 2007 |
Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
|
|
16 Oct 2007 |
Lexicon Reports Initial Clinical Trial Results for LX1031, An Investigational New Drug For Irritable Bowel Syndrome
|
|
16 Oct 2007 |
Dynogen's Oral Prokinetic Drug, DDP733, Shown to Reduce Reflux in Phase 1 B Study
|
|
16 Oct 2007 |
XenoPort and Xanodyne Announce Exclusive U.S. Licensing Agreement for XP21510
|
|
16 Oct 2007 |
Study Data Results Showed Desvenlafaxine Significantly Reduced Moderate to Severe Vasomotor Symptoms in Menopausal Women Versus Placebo
|
|
12 Oct 2007 |
BioXell announces positive Phase IIb results for Elocalcitol in Benign Prostatic Hyperplasia
|
|
12 Oct 2007 |
Clinical Benefits Demonstrated with Low-Dose GATTEX(TM) in Phase 3 Short Bowel Syndrome Study
|
|
12 Oct 2007 |
Affymax Doses First Patient in the Phase 3 Clinical Program of Hematide(TM) to Treat Anemia in Chronic Renal Failure Patients
|
|
10 Oct 2007 |
SALVAT has Completed Patient Enrollment in a Dose Finding Phase II Trial of SVT-40776 for the Treatment of Overactive Bladder
|
|
10 Oct 2007 |
Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
|
|
09 Oct 2007 |
Isis Receives $1.25 Million Milestone Payment From iCo for Initiation of Phase 1 Study of iCo-007
|
|
09 Oct 2007 |
Jerini Ophthalmic Treats First Patient in Phase I Trial for Age-related Macular Degeneration
|
|
09 Oct 2007 |
Sirtris Pharmaceuticals' Oral Drug Candidate SRT501 Shown To Be Neuroprotective: Implications for SIRT1 Activation in Neurodegenerative Eye Disorders
|
|
09 Oct 2007 |
Enrollment Complete in Pivotal Phase III Trial of Medidur(TM)FA for Diabetic Macular Edema
|
|
09 Oct 2007 |
Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohn's Disease
|
|
09 Oct 2007 |
Phase III Clinical Product Development Update
|
|
09 Oct 2007 |
Phase III clinical product development update
|
| |
|
Results 351 - 400 of 985 |
